Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellcome Trust Sanger Institute

www.sanger.ac.uk

Latest From Wellcome Trust Sanger Institute

Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding

With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.

Deals Financing

Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes

The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.

StartUps and SMEs Financing

Infectious Disease Companies Catch More Investors

Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.

BioPharmaceutical Medical Device

Venture Funding Deals, June 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2015.

BioPharmaceutical Medical Device
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register